Literature DB >> 24566183

Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.

Seyedmojtaba Seyedmousavi1, Roger J M Brüggemann, Willem J G Melchers, Paul E Verweij, Johan W Mouton.   

Abstract

Adequate penetration to the infection/colonization site is crucial to attain optimal efficacy of posaconazole against Aspergillus fumigatus diseases. We evaluated posaconazole exposure in pulmonary epithelial lining fluid (ELF) in a murine model of invasive pulmonary aspergillosis. The posaconazole exposure (area under the plasma concentration-time curve from time zero to 24 h postinfusion [AUC0-24]) in ELF was 20% to 31% of that in plasma for total drug after the third dose, and the relationship between plasma and ELF exposure was linear (r(2) = 0.97, P = 0.016).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24566183      PMCID: PMC3993253          DOI: 10.1128/AAC.00053-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 2.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

3.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors:  S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1986-02

4.  Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Authors:  Susan J Howard; Jodi M Lestner; Andrew Sharp; Lea Gregson; Joanne Goodwin; Joanne Slater; Jayesh B Majithiya; Peter A Warn; William W Hope
Journal:  J Infect Dis       Date:  2011-02-28       Impact factor: 5.226

5.  Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection.

Authors:  C P W G M Verweij-van Wissen; D M Burger; P E Verweij; R E Aarnoutse; R J M Brüggemann
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-01-25       Impact factor: 3.205

6.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Quantitative assessment of epithelial lining fluid in the lung.

Authors:  F P Chinard
Journal:  Am J Physiol       Date:  1992-12

8.  Bronchoalveolar lavage. Quantitation of intraalveolar fluid?

Authors:  P Von Wichert; K Joseph; B Müller; W M Franck
Journal:  Am Rev Respir Dis       Date:  1993-01

9.  Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.

Authors:  John E Conte; Jeffrey A Golden; Gopal Krishna; Marina McIver; Emily Little; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

10.  Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.

Authors:  Eveline Snelders; Henrich A L van der Lee; Judith Kuijpers; Anthonius J M M Rijs; János Varga; Robert A Samson; Emilia Mellado; A Rogier T Donders; Willem J G Melchers; Paul E Verweij
Journal:  PLoS Med       Date:  2008-11-11       Impact factor: 11.069

View more
  7 in total

1.  In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.

Authors:  Yu-Feng Zhou; Meng-Ting Tao; Wei Huo; Xiao-Ping Liao; Jian Sun; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.

Authors:  M J Melchers; E Mavridou; S Seyedmousavi; A C van Mil; C Lagarde; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

5.  Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

Authors:  Adela Martin-Vicente; Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

7.  In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice.

Authors:  Genki Kimura; Takahiro Nakaoki; Thomas Colley; Garth Rapeport; Pete Strong; Kazuhiro Ito; Yasuo Kizawa
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.